NCT01918995View on ClinicalTrials.gov

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Healthy Volunteers
Interventions
DRUG

Regadenoson

Intravenous (IV)

DRUG

Placebo

Intravenous (IV)

Trial Locations (1)

21225

Parexel Early Phase Unit, Baltimore

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT01918995 - Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects | Biotech Hunter | Biotech Hunter